ENVERIC BIOSCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $39.9M |
| Cost of Revenue | — | — | — | — | — | — | — | $31.8M |
| Gross Profit | — | — | — | — | — | — | — | $8.2M |
| Gross Margin | — | — | — | — | — | — | — | 20.4% |
| Operating Expenses | ||||||||
| Research & Development | — | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174.1K | — |
| SG&A Expense | — | $5.8M | $6.5M | $8.9M | $11.6M | $20.5M | $5.3M | $2.3M |
| Operating Income | — | $-8.8M | $-9.6M | $-16.4M | $-27.4M | $-64.6M | $-5.6M | $-2.3M |
| Operating Margin | — | — | — | — | — | — | — | -5.8% |
| Interest Expense | — | — | — | — | $5.2K | $10.3K | $445.3K | $81.8K |
| Pretax Income | — | $-8.8M | $-9.6M | $-17.3M | $-20.0M | $-56.4M | $-6.9M | $-5.2M |
| Income Tax Expense | — | — | $8.9K | $28.9K | $-1.5M | $-7.5M | — | $388.7K |
| Net Income | — | $-8.8M | $-9.6M | $-17.3M | $-18.5M | $-49.0M | $-6.9M | $-2.4M |
| Net Margin | — | — | — | — | — | — | — | -6.0% |
| EPS (Basic) | — | $-36.24 | $-28.56 | $-15.16 | $-1.63 | $-4.32 | $-0.05 | $-0.04 |
| EPS (Diluted) | — | $-36.24 | $-28.56 | $-15.16 | $-1.63 | $-0.09 | $-0.05 | $-0.04 |
| Shares Outstanding (Basic) | 1.9M | 334.7K | 335.3K | 1.2M | 11.6M | 11.3M | 138.1M | 380.7M |
| Shares Outstanding (Diluted) | 1.9M | 334.7K | 335.3K | 1.2M | 11.6M | 11.3M | 138.1M | 153.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |